Calcific Aortic Valve Disease: a Multidisciplinary Approach to Investigate the Role of Bacteria as Trigger of a Chronic Inflammation in the Pathogenesis of Calcification

Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia (Other)
Overall Status
Recruiting
CT.gov ID
NCT05806411
Collaborator
University of Pavia (Other)
44
1
24
1.8

Study Details

Study Description

Brief Summary

Calcific aoric valve disease (CAVD) is extremely common worldwide, affecting almost 50% of the population over 85 years of age, with a lethality higher than 50% at 2 years for symptomatic patients, unless aortic-valve replacement is performed. CAVD is characterized by slowly progressive fibro-calcific remodelling of the valve leaflets causing aortic stenosis. The spectrum of the disease progression starts with leaflet degeneration and progresses from early lesions to valve stenosis/obstruction, which is initially mild to moderate but eventually becomes severe. Risk factors for CAVD partly overlap those for atherosclerosis but also intake age-related tissue changes and effects of comorbiditiies (e.g. renal failure) in the overall complex mechanisms of valve leaflet degeneration, which is, at present, unpreventable, leaving aortic valve repair the only treatment option for severe aortic stenosis. In the first phase of the disease the valve becomes thickened and mildly calcified, then the disease evolves to severe valve calcification with impaired leaflet motion and vast blood flow obstruction. Calcific AS valves show advanced osteogenic metaplasia with the presence of osteoblast-like cells and chondrocytes associated with dense inflammatory infiltrates. Bacteria have been detected in the absence of diagnosis of acute infective endocarditis, but their role is still unknown. Different bacterial species (C. acnes (59%),

  1. faecalis (16%), S. aureus (15%), and S. pyogenes (10%)) have been typed and intramural bacterial colonization has been observed in patients with calcified structural valvular heart disease. Indeed, it has been recently demonstrated that bacterial infections can directly affect osteoblast differentiation/activation.

The Authors hypothesized that a subclinical or latent valvular bacterial infiltration facilitates a chronic inflammation and contributes to accelerated structural valve degeneration. An interdisciplinary team has been established to investigate the infective, biochemical and structural features of calcific aortic valve disease.

The primary objective of the study is to dissect the bacteria contribution to valve calcification. The Authors hypothesized that a subclinical or latent valvular bacterial infiltration facilitates a chronic inflammation and contributes to accelerated structural valve degeneration. The Authors expect to find a correlation between bacterial detection (as qualitative -positive/negative, quantitative -quantitative PCR) and bone calcification markers on valves. To dissect the bacteria contribution to valve calcification, the osteogenic differentiation capabilities of primary cells obtained from cusp explanted from control and from non-calcified cusp of CAVD patients will be assessed in vitro in absence and in presence of bacterial infection. There are currently no data in the literature that can be referred to for the calculation of the sample size. Cusp calcifications do not equally affect all cusps, considering calcified cusp as cases and non-calcified cusp of the same valve as matched controls, if the probability of bacterial detection among sampled control non calcified cusps is 10% (Cohen, doi: 10.1016/S0003-4975(03)01454-1), a sample of 32 patients (with 32 calcified cusp and 96cusps) can be enrolled. This sample of 96 cusps achieves 81% power to detect an odds ratio of 5.00 versus the alternative of equal odds using a McNemar test with a 0.05 significance level. This calculation is done considering that the probability of bacterial detection in each cusp is almost independent from other cusps of the same valve (intra-valve correlation coefficient= 0.10). The Authors expect a total study duration of 24 months. The Authors estimate to complete recruitment in 12 months. The estimated primary completion is month 15 (3 months after last subject enrollment) and study completion on month 24 (12 months after last patient inclusion)

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Analysis of calcific aortic valves

Study Design

Study Type:
Observational
Anticipated Enrollment :
44 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Calcific Aortic Valve Disease: a Multidisciplinary Approach to Investigate the Role of Bacteria as Trigger of a Chronic Inflammation in the Pathogenesis of Calcification
Actual Study Start Date :
Jan 18, 2023
Anticipated Primary Completion Date :
Jan 18, 2024
Anticipated Study Completion Date :
Jan 18, 2025

Arms and Interventions

Arm Intervention/Treatment
Patients

Patients with calcific aortic sclerosis (stage III and IV) that are going to be treated with traditional surgery according to International Guidelines will be enrolled as cases.

Diagnostic Test: Analysis of calcific aortic valves
Microbiologic analysis of calcofic aortic valves

Controls

Patients that will undergo a cardiac transplantation (for nonvalvular cardiac disease) or patients with aortic valve insufficiency will be enrolled as controls

Diagnostic Test: Analysis of calcific aortic valves
Microbiologic analysis of calcofic aortic valves

Outcome Measures

Primary Outcome Measures

  1. To analyze subclinical or latent valvular bacterial infiltration in patients with calcific aortic disease [2 years]

    Rate of bacterial infiltration in calcified and non calcified cusps and in patients and controls (co-primary endpoint) will be analysed.

  2. To evaluate the correlation between bacterial detection (as qualitative-positive/negative-, quantitative -quantitative PCR-) and bone calcification markers on valves [2 years]

    Rate of expression of osteogenic markers and total calcium valve content in calcified and non-calcified cusps on valves of patients and controls and correlation with bacterial detection

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age>18 years.

  • Calcific aortic sclerosis (stage III and IV)

Exclusion Criteria:
  • Inability to comply with the requirements of the protocol.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fondazione IRCCS Policlinico San MAtteo Pavia Italy 27100

Sponsors and Collaborators

  • Fondazione IRCCS Policlinico San Matteo di Pavia
  • University of Pavia

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Fondazione IRCCS Policlinico San Matteo di Pavia
ClinicalTrials.gov Identifier:
NCT05806411
Other Study ID Numbers:
  • CAvD
First Posted:
Apr 10, 2023
Last Update Posted:
Apr 13, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Fondazione IRCCS Policlinico San Matteo di Pavia
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 13, 2023